Sunday, September 18, 2011

Qualitest recalls birth control pills: FDA

(Reuters) - Qualitest Pharmaceuticals is voluntarily recalling several lots of birth control pills because of a packaging error that could leave women at risk for unplanned pregnancy, the U.S. Food and Drug Administration (FDA) said.

Select blisters were rotated 180 degrees within the card, reversing the weekly tablet orientation and making the lot number and expiration date no longer visible, the FDA said in a statement on its website.

The error means the daily regimen for the oral contraceptives may be incorrect and could leave women at risk of an unplanned pregnancy, it said. The defects do not pose any immediate health risks.

"This packaging error and the potential for this error to have affected other oral contraceptive products resulted in the company issuing the recall of multiple lots," the agency said.

The recall takes effect immediately. It includes Cyclafem 7/7/7, Cyclafem 1/35, Emoquette, Gildess FE 1.5/30, Gildess FE 1/20, Orsythia, Previfem and Tri-Previfem.

The affected lot numbers can be found here

Qualitest is a unit of Endo Pharmaceuticals Holdings Inc.

(Reporting by Ian Simpson; editing by Cynthia Johnston and Andre Grenon)

The information contained on(the "Site") is provided for informational purposes only and is not meant to substitute for advice from your doctor or healthcare professional. This information should not be used for diagnosing or treating a health problem or disease, or prescribing any medication. Always seek the advice of a qualified healthcare professional regarding any medical condition. Information and statements provided by the site about dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Lifescript does not recommend or endorse any specific tests, physicians, third-party products, procedures, opinions, or other information mentioned on the Site. Reliance on any information provided by (THE SITE) is solely at your own risk.

No comments:

Post a Comment